187 related articles for article (PubMed ID: 37221258)
21. In Silico Investigations of Multi-Drug Adaptive Therapy Protocols.
Thomas DS; Cisneros LH; Anderson ARA; Maley CC
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681680
[TBL] [Abstract][Full Text] [Related]
22. Do mechanisms matter? Comparing cancer treatment strategies across mathematical models and outcome objectives.
Buhler CK; Terry RS; Link KG; Adler FR
Math Biosci Eng; 2021 Jul; 18(5):6305-6327. PubMed ID: 34517535
[TBL] [Abstract][Full Text] [Related]
23. Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study.
Gagel B; Piroth M; Pinkawa M; Reinartz P; Krohn T; Kaiser HJ; Stanzel S; Breuer C; Asadpour B; Schmachtenberg A; Eble MJ
BMC Cancer; 2007 Jun; 7():112. PubMed ID: 17598906
[TBL] [Abstract][Full Text] [Related]
24. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy.
Huo TI; Hsu CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Chiang JH; Lee PC; Lee SD
BMC Gastroenterol; 2010 Dec; 10():146. PubMed ID: 21194431
[TBL] [Abstract][Full Text] [Related]
25. Multiple machine implementation of enhanced dynamic wedge.
Klein EE; Gerber R; Zhu XR; Oehmke F; Purdy JA
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):977-85. PubMed ID: 9531384
[TBL] [Abstract][Full Text] [Related]
26. Local changes in snow depth dominate the evolving pattern of elevation-dependent warming on the Tibetan Plateau.
Guo D; Pepin N; Yang K; Sun J; Li D
Sci Bull (Beijing); 2021 Jun; 66(11):1146-1150. PubMed ID: 36654348
[TBL] [Abstract][Full Text] [Related]
27. Total tumour volume as a prognostic factor in patients with resectable colorectal cancer liver metastases.
Tai K; Komatsu S; Sofue K; Kido M; Tanaka M; Kuramitsu K; Awazu M; Gon H; Tsugawa D; Yanagimoto H; Toyama H; Murakami S; Murakami T; Fukumoto T
BJS Open; 2020 Jun; 4(3):456-466. PubMed ID: 32277807
[TBL] [Abstract][Full Text] [Related]
28. A Fair Chance for Everyone: Total Tumor Volume as a Selection Tool in Liver Transplantation for Hepatocellular Carcinoma.
Pinto-Marques H; Silva S; Sobral M; Perdigoto R; Martins A; Barroso E
Dig Surg; 2018; 35(6):539-548. PubMed ID: 29346782
[TBL] [Abstract][Full Text] [Related]
29. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R
Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174
[TBL] [Abstract][Full Text] [Related]
30. Using histopathology breast cancer data to reduce clinical target volume margins at radiotherapy.
Stroom J; Schlief A; Alderliesten T; Peterse H; Bartelink H; Gilhuijs K
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):898-905. PubMed ID: 19409724
[TBL] [Abstract][Full Text] [Related]
31. α-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma.
Lee YH; Hsu CY; Huang YH; Su CW; Lin HC; Hsia CY; Huo TI
J Gastrointest Surg; 2013 Apr; 17(4):730-8. PubMed ID: 23188220
[TBL] [Abstract][Full Text] [Related]
32. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Potter DM
Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
[TBL] [Abstract][Full Text] [Related]
33. Impact of dose size in single fraction spatially fractionated (grid) radiotherapy for melanoma.
Zhang H; Zhong H; Barth RF; Cao M; Das IJ
Med Phys; 2014 Feb; 41(2):021727. PubMed ID: 24506618
[TBL] [Abstract][Full Text] [Related]
34. Comparison of dosimetric characteristics of physical and enhanced dynamic wedges.
Saminathan S; Manickam R; Supe SS
Rep Pract Oncol Radiother; 2011; 17(1):4-12. PubMed ID: 24376991
[TBL] [Abstract][Full Text] [Related]
35. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
36. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Rangwala R; Leone R; Chang YC; Fecher LA; Schuchter LM; Kramer A; Tan KS; Heitjan DF; Rodgers G; Gallagher M; Piao S; Troxel AB; Evans TL; DeMichele AM; Nathanson KL; O'Dwyer PJ; Kaiser J; Pontiggia L; Davis LE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1369-79. PubMed ID: 24991839
[TBL] [Abstract][Full Text] [Related]
38. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.
Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA
Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708
[TBL] [Abstract][Full Text] [Related]
39. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm.
Tsur N; Kogan Y; Avizov-Khodak E; Vaeth D; Vogler N; Utikal J; Lotem M; Agur Z
J Transl Med; 2019 Oct; 17(1):338. PubMed ID: 31590677
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
